newsfilter
← Latest News
GlobeNewswire·

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

  • Jade Biosciences will present preclinical safety & translational data for JADE101 at two poster sessions during ASN Kidney Week 2025 in Houston.
  • JADE101 is an investigational, half-life extended, fully human monoclonal antibody designed to selectively inhibit APRIL for treating IgA nephropathy.
  • The company is currently conducting a Phase 1 healthy volunteer study with interim data expected in the first half of 2026.
  • Preclinical studies in non-human primates showed potent IgA suppression after a single dose with a serum half-life of approximately 27 days.
  • The two scheduled presentations on November 8, 2025, cover the nonclinical safety profile & a translational framework to predict clinical responses.
  • JADE101 is engineered to avoid high molecular weight immune complexes to support predictable pharmacokinetics & reduced immunogenicity risk.
  • Its differentiated pharmacokinetic profile supports potential infrequent subcutaneous dosing for conditions requiring long-term treatment.
  • Jade Biosciences also has a second candidate JADE201 & an undisclosed program JADE-003 in preclinical development.